Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168463 | 1.00 | LMNA (0.52) | LMNAMAPK1ACP3ESR1ALDH1A1 | |
| SCHEMBL538051 | 1.00 | LMNA (0.52) | LMNAMAPK1ACP3ESR1ALDH1A1 | |
| SCHEMBL28545652 | 0.98 | LMNA (0.50) | LMNAMAPK1ACP3ESR1ALDH1A1 | |
| 1,2-Dichlorobenzene SCHEMBL27641832 | 0.91 | FABP4 (0.46) | LMNAMAPK1ACP3ESR1ALDH1A1 | |
| SCHEMBL275598 | 0.84 | LMNA (0.64) | LMNAMAPK1ALDH1A1L3MBTL1POLB | |
| SCHEMBL28143820 | 0.83 | LMNA (0.43) | LMNAMAPK1ACP3ALDH1A1L3MBTL1 | |
| SCHEMBL21552683 | 0.83 | ESR1 (0.45) | LMNAMAPK1ACP3ESR1ALDH1A1 | |
| SCHEMBL124623 | 0.83 | ESR1 (0.45) | LMNAMAPK1ACP3ESR1ALDH1A1 | |
| SCHEMBL27719983 | 0.82 | ALDH1A1 (0.41) | LMNAMAPK1ALDH1A1FABP4FABP5 | |
| SCHEMBL959019 | 0.82 | CES2 (0.57) | LMNAACP3ESR1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340770-A | Coating material for waterproof coiled material, preparation method of coating material and waterproof coiled material | 福建科顺新材料有限公司 | 2022-11-15 | — | — | CN | claimed |
| EP-2543661-B1 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING BV (NL) | 2016-12-07 | — | — | EP | claimed |
| EP-2331545-B1 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE&NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LTD (IN) | 2013-10-02 | — | — | EP | claimed |
| US-8476437-B2 | Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2013-07-02 | — | — | US | claimed |
| EP-1778265-B1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | FERRING BV (NL) | 2013-04-24 | — | — | EP | claimed |
| EP-2543661-A1 | Guanylhydrazone compounds, compositions, methods of making and using | Cytokine Pharmasciences, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| US-8247455-B2 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING B.V. (NL) | 2012-08-21 | — | — | US | claimed |
| US-20110213149-A1 | PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-09-01 | — | — | US | claimed |
| US-7985572-B2 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF SE (DE) | 2011-07-26 | — | — | US | claimed |
| EP-2331545-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE&NEW IMPURITIES IN PREPARATION THEREOF | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| US-7863334-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-01-04 | — | — | US | claimed |
| WO-2010032264-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| CN-101602758-A | The intermediates preparation that is used for synthetic antiulcer agent compound | IL YANG PHARM CO LTD (KR) | 2009-12-16 | — | — | CN | claimed |
| EP-1599584-B1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF SE (DE) | 2009-07-01 | — | — | EP | claimed |
| US-20060259999-A1 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-16 | — | — | US | claimed |
| EP-1599584-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2004076655-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-10 | — | — | WO | claimed |
| EP-4729073-A1 | SYNTHETIC VACCINES AGAINST FRANCISELLA TULARENSIS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-0334538-A1 | Therapeutically useful tetralin derivatives | THE UPJOHN COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0064964-B1 | THERAPEUTICALLY USEFUL 1-ALKYL-2-AMINOTETRALIN DERIVATIVES | Astra Läkemedel Aktiebolag (SE) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213149-A1 | PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | BPNT1, GART, SLC7A1 | LMNA 2366/4885MAPK1 822/4885ACP3 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.